Skip to content

Ketamine: all studies

Page 241 of 449: studies 2,401 to 2,410 of 4,483, newest first. Back to the ketamine overview

Research

Antidepressant-relevant concentrations of the ketamine metabolite (2R,6R)-hydroxynorketamine do not block NMDA receptor function

Proceedings of the National Academy of Sciences February 22, 2019 E. Lumsden, Timothy A. Troppoli, S. J. Myers et al. 159 citations

Significance Standard antidepressant treatments require weeks to show effectiveness. A single subanesthetic dose of ketamine rapidly attenuates many clinical signs and symptoms of depression; however, ketamine treatment also has many adverse effects, including dissociation and potential for abuse, which are mediated by NMDA glutamate receptor (NMDAR) inhibition. Previous work has revealed that...

Reduced auditory evoked gamma-band response and schizophrenia-like clinical symptoms under subanesthetic ketamine

Neuropsychopharmacology February 6, 2019 Stjepan Curic, Gregor Leicht, Stephanie Thiebes et al.

Abnormal gamma-band oscillations (GBO) have been frequently associated with the pathophysiology of schizophrenia. GBO are modulated by glutamate, a neurotransmitter, which is continuously discussed to shape the complex symptom spectrum in schizophrenia. The current study examined the effects of ketamine, a glutamate N-methyl-d-aspartate receptor (NMDAR) antagonist, on the auditory-evoked...

Disentangling the association of depression on the anti-fatigue effects of ketamine.

Journal of Affective Disorders February 1, 2019 Leorey N Saligan, Cristan A Farmer, Elizabeth D. Ballard et al.

Fatigue and depression are closely associated. The purpose of this secondary analysis was to understand the relationships between depression and improvements in specific depression domains on the anti-fatigue effects of ketamine, which we previously reported. This secondary analysis re-evaluated data collected longitudinally from 39 patients with treatment-resistant Major Depressive Disorder...

Neuronal glutamatergic changes and peripheral markers of cytoskeleton dynamics change synchronically 24 h after sub-anaesthetic dose of ketamine in healthy subjects.

Behavioural Brain Research February 1, 2019 Lejla Colic, Conor McDonnell, Meng Li et al.

Ketamine acts as a rapid-acting antidepressant by restoring glutamatergic deficits and activating synaptic plasticity processes, with peak activity 24 h after infusion. Microtubule dynamics are known to play a key role in modulation of cytoskeleton and synaptic plasticity, as well as in signalling events in peripheral blood cells. Here, we correlated ketamine-induced change in...

Episodic-like memory impairment induced by sub-anaesthetic doses of ketamine.

Behavioural Brain Research February 1, 2019 Ingrid Brasilino Montenegro Bento De Souza, Ywlliane da Silva Rodrigues Meurer, Priscila Macedo Tavares et al.

Episodic-like memory refers to integration of where and when a certain event (what) happened. The glutamatergic neurotransmission, particularly AMPA and NMDA receptors, in the dorsal hippocampus mediates episodic recall. Ketamine is a non-competitive NMDA antagonist with effect on cognitive performance and plasticity. The goal of this study was to evaluate the acute action of ketamine on...

ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with Treatment-resistant Depression: The ELEKT-D study protocol.

Contemporary Clinical Trials February 1, 2019 S. Mathew, S. Wilkinson, Murat Altinay et al. 54 citations

Major depressive disorder (MDD) is the most common mental illness and the leading cause of disability worldwide. Electroconvulsive therapy (ECT) is the most effective treatment for MDD and the gold-standard therapy for treatment-resistant depression (TRD), yet it remains underutilized due to factors such as limited availability, stigma, and concerns about cognitive side effects. Ketamine has...

Synaptic potentiation and rapid antidepressant response to ketamine in treatment-resistant major depression: A replication study.

Psychiatry Research Neuroimaging January 30, 2019 Allison C. Nugent, Kathleen E. Wills, Jessica R. Gilbert et al.

Preclinical and clinical evidence has demonstrated that ketamine has rapid antidepressant effects. Studies using pre-treatment with an AMPA inhibitor suggest that enhancing AMPA throughput is crucial to ketamine's effects, including increases in both basal and evoked gamma power. This study sought to replicate previous findings of increased gamma response to a somatosensory stimulus at 230 min...

Temporal dynamics of the pharmacological MRI response to subanaesthetic ketamine in healthy volunteers: A simultaneous EEG/fMRI study

Journal of Psychopharmacology January 21, 2019 Rebecca McMillan, Anna Forsyth, Doug Campbell et al. 23 citations

BACKGROUND: Pharmacological magnetic resonance imaging has been used to investigate the neural effects of subanaesthetic ketamine in healthy volunteers. However, the effect of ketamine has been modelled with a single time course and without consideration of physiological noise. AIMS: This study aimed to investigate ketamine-induced alterations in resting neural activity using conventional...

DOI: 10.1177/0269881118822263 (opens in new tab) Ketamine Blood-oxygen-level dependent Electroencephalography Anterior cingulate cortex +5